# NCT05218499 (NCT05218499)

> Brightline-1: A Study to Compare Brigimadlin (BI 907828) With Doxorubicin in People With a Type of Cancer Called Dedifferentiated Liposarcoma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05218499
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Boehringer Ingelheim
- Conditions: Liposarcoma, Dedifferentiated
- Interventions: Brigimadlin; Doxorubicin
- Enrollment: 400
- Primary outcome: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 10
- X threads: 10
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct05218499

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05218499", "email": "<work email>"}; the inbox owner confirms by the emailed link.